<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00346255</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000491241</org_study_id>
    <secondary_id>IMMUNO-003</secondary_id>
    <secondary_id>DFCI-05031</secondary_id>
    <nct_id>NCT00346255</nct_id>
    <nct_alias>NCT00625508</nct_alias>
  </id_info>
  <brief_title>BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma</brief_title>
  <acronym>IMGN901</acronym>
  <official_title>A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunoGen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmunoGen, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as BB-10901, can block cancer growth in different&#xD;
      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and&#xD;
      help kill them or carry cancer-killing substances to them.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of BB-10901 in&#xD;
      treating patients with relapsed and/or refractory multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the dose-limiting toxicity and the maximum tolerated dose of BB-10901 in&#xD;
           patients with relapsed and/or refractory CD56-positive multiple myeloma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the qualitative and quantitative toxicities of BB-10901 administered on&#xD;
           this schedule.&#xD;
&#xD;
        -  To evaluate the pharmacokinetics of BB-10901.&#xD;
&#xD;
        -  To recommend a dose for Phase II clinical studies with BB-10901 given on this specific&#xD;
           regimen.&#xD;
&#xD;
        -  To observe any evidence of anti-tumor activity with BB-10901.&#xD;
&#xD;
      Objectives of MTD Expansion Cohort&#xD;
&#xD;
        -  To evaluate response rate including overall response rate (ORR) and complete response&#xD;
           rate (CRR), and duration of response (DOR).&#xD;
&#xD;
        -  To further assess time to progression (TTP), progression free survival (PFS), and&#xD;
           overall survival (OS).&#xD;
&#xD;
      OUTLINE: This is an open-label, non-randomized, dose-escalation, multicenter study.&#xD;
&#xD;
      Patients receive BB-10901 IV over 1-2 hours on days 1 and 8. Courses repeat every 21 days in&#xD;
      the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of BB-10901 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients&#xD;
      experience dose-limiting toxicity. Up to 40 patients are treated at the MTD.&#xD;
&#xD;
      After completion of study treatment, patients are followed for short term follow-up and long&#xD;
      term (up to 3 years) survival status.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 80 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity</measure>
    <time_frame>through cycle 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>for the duration of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Qualitative and quantitative toxicities</measure>
    <time_frame>for the duration of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>for the duration of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity including overall response rate, time to progression and survival</measure>
    <time_frame>for the duration of the study</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">37</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BB-10901</intervention_name>
    <description>dose escalation study, doses will vary per cohort. patients will receive an IV infusion weekly for two weeks every three weeks.</description>
    <other_name>IMGN901</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed multiple myeloma&#xD;
&#xD;
          -  Relapsed or relapsed/refractory disease&#xD;
&#xD;
               -  Failed ≥ 1 prior therapy for multiple myeloma&#xD;
&#xD;
               -  Once the MTD is defined, only patients who have received at least 1 but equal or&#xD;
                  less than 6 prior chemotherapy regimens will be enrolled at this dose level&#xD;
&#xD;
          -  CD56-positive disease confirmed by immunohistochemistry or flow cytometry&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG (Zubrod) performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8.5 g/dL&#xD;
&#xD;
          -  AST and ALT ≤ 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  Amylase and lipase within normal limits&#xD;
&#xD;
          -  Creatinine ≤ 2 mg/dL&#xD;
&#xD;
          -  Left ventricular ejection fraction ≥ lower limit of normal on MUGA or ECHO&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 3 or painful grade 2 neuropathy&#xD;
&#xD;
          -  No significant cardiac disease, including any of the following:&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Uncontrolled congestive heart failure&#xD;
&#xD;
               -  Uncontrolled hypertension (i.e., recurrent or persistent increases in systolic&#xD;
                  blood pressure ≥ 180 mm Hg or diastolic blood pressure ≥ 110 mm Hg)&#xD;
&#xD;
               -  Uncontrolled cardiac arrhythmias&#xD;
&#xD;
               -  Cardiac toxicity ≥ grade 3 after prior chemotherapy&#xD;
&#xD;
          -  No history of multiple sclerosis or other demyelinating disease&#xD;
&#xD;
          -  No hemorrhagic or ischemic stroke within the past 6 months&#xD;
&#xD;
          -  No Eaton-Lambert syndrome (para-neoplastic syndrome)&#xD;
&#xD;
          -  No CNS injury with residual neurological deficit (other than peripheral neuropathy ≤&#xD;
             grade 2)&#xD;
&#xD;
          -  No other malignancy within the past 3 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer, in situ cervical cancer, in situ breast cancer, or in situ&#xD;
             prostate cancer&#xD;
&#xD;
          -  No clinically relevant active infection, including active hepatitis B or C infection&#xD;
             or HIV infection&#xD;
&#xD;
          -  No other condition or disease, including laboratory abnormalities, that, in the&#xD;
             opinion of the investigator, may preclude study treatment&#xD;
&#xD;
          -  No known recent biochemical or clinical evidence of pancreatitis or extensive&#xD;
             metastatic disease involving the pancreas&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery (except placement of a vascular access&#xD;
             device or tumor biopsies)&#xD;
&#xD;
          -  More than 4 weeks since prior investigational agents&#xD;
&#xD;
          -  At least 2 weeks since prior antineoplastic therapy with biological agents&#xD;
&#xD;
          -  No prior hypersensitivity to monoclonal antibody therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent corticosteroids (except as indicated for other medical conditions [&lt; 10&#xD;
             mg prednisone or equivalent]; as pre-medication for administration of certain&#xD;
             medications or blood products [≤ 100 mg hydrocortisone]; or for treatment of infusion&#xD;
             reactions)&#xD;
&#xD;
               -  Concurrent topical steroids allowed&#xD;
&#xD;
          -  No other concurrent antineoplastic treatment (e.g., chemotherapy, radiotherapy, or&#xD;
             biological agents)&#xD;
&#xD;
          -  Concurrent bisphosphonates allowed provided patient began bisphosphonates before study&#xD;
             entry and is maintained on a stable dose during study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asher Alban Akmal Chanan-Khan,, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Outpatient Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Comprehensive Cancer Center - Manhattan</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gascon 450 - (C1181ACH)</name>
      <address>
        <city>Buenos Aires</city>
        <state>Capital Federal</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juan Domingo Peron 1500 - (B1629AHJ) Pilar</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Av. Naciones Unidas 346. (X5016KEH)-Barrio Parque Velez Sarfield</name>
      <address>
        <city>Córdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>June 28, 2006</study_first_submitted>
  <study_first_submitted_qc>June 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2006</study_first_posted>
  <last_update_submitted>April 22, 2013</last_update_submitted>
  <last_update_submitted_qc>April 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lorvotuzumab mertansine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

